Dr. Jacobson on the Interim Analysis of the MZL Cohort in the ZUMA-5 Trial
August 11th 2020Caron Jacobson, MD, discusses the interim analysis results of the marginal zone lymphoma cohort in the phase 2 ZUMA-5 study with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.
Read More